NEW YORK, March 4 () - UniQure's trial design for its gene therapy for Huntington's disease did not offer sufficient proof that the drug slowed disease progression, ‌a top U. Food and Drug ...

Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and tolerability findings MIAMI, FLORIDA / ACCESS Ne ...

What if stumbling upon a product makes you love it more? Science says this is true. And the reason why reveals something ...

Clinical trials can vary in length depending on several factors. Here's what you need to know about how long clinical trials last.

A key advantage of using RWD in a natural history study is gaining diverse and representative data. RWD covers broad patient populations, including those with comorbidities, various age groups, and ...

Excessive mobile gaming is raising concerns about health and sleep, but research from Kyushu University suggests that small changes can help. In a global study involving over 80,000 players, the team ...

In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for ...

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs ...

The May 29, 2026 PDUFA targets pediatric approval of Afrezza for type 1 or type 2 diabetes, leveraging INHALE-1 outcomes versus rapid-acting analogs plus basal insulin. INHALE-1 was open-label and ...

KALAMAZOO, Mich.—Breaking through long-standing norms, a team of interdisciplinary researchers from Western Michigan ...

The University of Warwick, which is setting up the Registry, plans to collect data for analysis from 500 AML patients at sites in 30 large metropolitan NHS hospitals across the UK by the end of this ...

Disitamab vedotin has shown antitumor activity in HER2-expressing subgroups with pretreated, locally advanced unresectable or metastatic urothelial cancer.